Skip to content
value.today

IRulya Therapeutics Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Your own DCF model

A full discounted-cash-flow model of IRulya Therapeutics Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025—$-84 M$-41 M$0 M$-42 M$-6 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024—$-57 M$-32 M$0 M$-32 M$8 MSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023—$-31 M$-18 M$0 M$-18 M$-7 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022—$-52 M$-44 M$0 M$-44 M$-41 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021—$-90 M$-63 M$0 M$-63 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020—$-77 M$-51 M$0 M$-51 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $343 M on Oct 30, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.